Eton Pharmaceuticals Inc (ETON) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Eton Pharmaceuticals Inc   (NASDAQ: ETON)


Eton Pharmaceuticals Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Eton Pharmaceuticals Inc's ROI in the second quarter of 2026?
Eton Pharmaceuticals Inc achieved a return on average invested assets (ROI) of 21.31 % in its second quarter of 2026 a new company high.

ROI has improved compared to -2.56% in the first quarter of 2026, due to net income growth.

Within the Healthcare sector 37 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2372 to 2732.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 22.74 % 59.48 % 132.5 % 292.48 % 195.2 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 71 54 54 60 63
Return On Investment (TTM) 21.31 % -2.56 % -7.81 % -11.22 % -8.51 %
ETON's Overall Ranking # 2732 # 2372 # 2531 # 2325 # 2706
Seq. Investment Change TTM 3.3 % -2.19 % -1.07 % 22.79 % 34.22 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions 13 -1 -5 -7 -4

ETON Company Profile >> Back to ETON Roi Comparisons >> See Annual ETON Return On Investment



Return On Investment ETON's Ranking
Within: No.
Industry # 17
Sector # 38
Overall # 2732

Return On Investment Statistics
High Average Low
21.31 %
-56.37 %
-230.03 %
(Jun 30 2026)   (Sep 30 2018)



  News about Eton Pharmaceuticals Inc Return on Investment ROI

Eton Pharmaceuticals' Hydrocortisone Oral Solution Prepares for FDA Decision as Share Price Rises

July 15, 2024



In an exciting development for Eton Pharmaceuticals, the company recently announced that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for ET-400, a Hydrocortisone Oral Solution. The Prescription Drug User Fee Act (PDUFA) target action date for the drug s approval is set for February 28, 2025. As Eton anticipates this decisive date, investors have taken notice, driving ETON shares to a notable 4.57% increase in the last five trading days. Let us delve into the upcoming FDA decision and the reasons behind Eton s soaring stock performance.
The Promise of Hydrocortisone Oral Solution:
ET-400, Eton Pharmaceuticals Hydrocortisone Oral Solution, holds significant promise as a potential treatment option. Hydrocortisone, a steroid hormone, is widely recognized for its anti-inflammatory and immunosuppressive properties. The oral solution aims to provide relief to patients suffering from adrenal insufficiency, a condition caused by a lack of cortisol production by the adrenal glands. If approved, ET-400 could make a substantial difference in the lives of patients, alleviating their symptoms and improving their overall well-being.





Financial Statements
Eton Pharmaceuticals Inc's II. Quarter Investments $ 71 Millions ETON's Balance sheet
Eton Pharmaceuticals Inc's II. Quarter Income $ 12 Millions Quarterly ETON's Income Statement
ETON's Income by Division See ETON's Income by Division


ETON Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 54 56 15 19 23
Y / Y Investment Growth -4.54 % 262.45 % -16.53 % -18.94 % 1.7 %
Net Income in Millions -5 -4 -1 -9 -2
Y / Y Net Income Growth - - - - -
Annual Return On Investment -8.58 % -6.81 % -6.04 % -48.58 % -8.53 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ETON's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ETON's Competitors
Subscribers only: Roi for Eton Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for ETON's Customers

Other Ratios
ETON's Roa ETON's Inventory Turnover Ratio ETON's Growth Rates ETON's Dividend Statistics
ETON's Profitability Ratios ETON's Asset Turnover Ratio ETON's Dividend Growth
ETON's Roe ETON's Valuation Ratios ETON's Financial Strength Ratios ETON's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Meiragtx Holdings Plc  55.83 %
Elite Pharmaceuticals Inc   53.48 %
Idexx Laboratories Inc  51.80 %
Aurinia Pharmaceuticals Inc   50.35 %
Qhslab Inc   48.94 %
Q32 Bio Inc   47.43 %
Vaxart Inc   46.17 %
Liquidia Corporation  42.09 %
Tg Therapeutics Inc   39.26 %
Medpace Holdings Inc   35.54 %
Mettler toledo International Inc   34.41 %
Eli Lilly And Company  33.95 %
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %
Adma Biologics Inc   28.94 %
Protalix Biotherapeutics inc   25.72 %
Pro dex Inc   24.29 %
Innoviva Inc   23.33 %
Electromed Inc   23.18 %
Zevra Therapeutics Inc   22.90 %
Iradimed Corporation  22.57 %
Alnylam Pharmaceuticals Inc   22.10 %
Eton Pharmaceuticals Inc   21.31 %
Dexcom Inc   20.98 %
Healthcare Services Group Inc   20.93 %
Arcutis Biotherapeutics Inc   20.77 %
Chemed Corporation  20.13 %
Resmed Inc   20.01 %
Halozyme Therapeutics Inc   19.99 %
Vertex Pharmaceuticals Inc  19.97 %

Date modified: 2026-09-08T17:36:09+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.